In the past week, there were 340 stocks surveyed by institutions.

In the past week, Montage Technology (688008) has received a total of 319 institutions to participate in the survey, including 60 fund companies, 62 securities companies, 84 insurance companies, etc.

In 2024, the company will achieve operating income of about 3.639 billion yuan, a year-on-year increase of 59.20%; the net profit attributable to the parent company was 1.412 billion yuan, a year-on-year increase of 213.1%; the net profit deducted from non-attributable to the parent company was 1.248 billion yuan, a year-on-year increase of 237.44%; The net cash flow from operating activities was 1.691 billion yuan, a year-on-year increase of 131.29%, and continued to grow for three consecutive years.

In the first quarter of 2025, the company expects to achieve operating income of about 1.222 billion yuan, a year-on-year increase of about 65.78% and a quarter-on-quarter increase of about 14.42%; The net profit attributable to the parent company was 510 million yuan to 550 million yuan, a year-on-year increase of 128.28%-146.19% and a month-on-month increase of 17.59%-26.82%; The non-net profit attributable to the parent company was 485 million yuan to 525 million yuan, an increase of 120.82% to 139.03% year-on-year and 29.52% to 40.2% month-on-month.

In terms of market value management, Montage Technology's profit distribution plan for 2024 is to distribute a cash dividend of RMB 3.90 (tax included) per 10 shares, with an estimated cash dividend of RMB 443 million, and a repurchase amount of RMB 409 million in 2024, with an estimated total cash dividend and repurchase amount of approximately RMB 852 million, accounting for 60% of the Company's net profit attributable to owners of the parent company in 2024, demonstrating the Company's positive feedback to shareholders in the long term.

Nine Company, Huaming Equipment (002270), Xu Ji Electric (000400), Rongchang Biotechnology and other stocks have also been investigated by more than 100 institutions, among which Daikin Heavy Industries (002487) and Sinovac Pharmaceutical have performed better this week.

Daikin Heavy Industries' stock price rose more than 18% in a week, hitting a new high for the year. Benefiting from the high profitability brought by the high added value of exported offshore products, the company achieved a net profit attributable to the parent company of 474 million yuan, an increase of 11.46% year-on-year, and the overall gross profit margin and net profit margin continued to increase for three consecutive years. Due to the high quality of payment collection from overseas customers and the company's strengthened collection control of domestic business, the company will achieve a net operating cash flow of 1.083 billion yuan in 2024, an increase of 275 million yuan compared with the previous year, and continue to increase for three consecutive years.

Daikin Heavy Industries said in the survey that the trend of large-scale wind turbines in the global market has been very clear, and the demand for large megawatt wind turbine components is surging, but the lag of the supply chain and supporting facilities has become a key bottleneck. At present, the market has insufficient supporting capacity such as large wind power carriers and installation ships, especially for the future deep-sea market, and the gap between supply and demand may expand in the short term.

After the release of the annual report, a number of institutions such as Soochow Securities (601555), Minsheng Securities, Zheshang Securities (601878), and Great Wall Securities (002939) raised their performance expectations for Daikin Heavy Industries this year.

Great Wall Securities said that Daikin Heavy Industries offshore equipment leads the European market, the competitiveness of the "two seas" continues to strengthen, and it is expected to usher in a double peak of overseas order delivery and new order acquisition in the context of the recovery of global sea breeze demand and the accelerated release of orders. At the same time, it is compatible with the development of autonomous transportation, floating and new energy power generation, and is optimistic about long-term performance.

Sinovac Pharmaceutical's share price also hit a new high this week. In 2024, the company's overall operating quality will be significantly improved, its main business will continue to improve steadily, its internationalization strategy will achieve a breakthrough in the EU market, and its overseas revenue will increase significantly. The domestic market grew steadily, and the market share remained leading; Efficiently promote the R&D pipeline, and the data of multiple innovative drug pipelines are excellent; The precise allocation of resources and the reduction of costs and efficiency increase of the whole chain have achieved remarkable results.

Multiple institutional research stocks

The stock price hit a new high

A-shares continued to rebound this week, with the Shanghai Composite Index rising 1.19% for the week, approaching the 3,300-point mark. It was found that institutional research stocks rose by 0.87% on average, and the largest increase was consistent konjac, with a cumulative increase of more than 55%, and the stock price frequently hit record highs.

The company pointed out in the survey that at present, the trend of domestic konjac prices this year depends on the actual planting area in the country in 2025, as well as the weather and climate conditions this year, which have a direct impact on the output and lead to price fluctuations. The company judged that the planting area of konjac may increase, and the downstream demand will also increase, and the price of konjac raw materials in the future will still depend on the relationship between supply and demand.

Minshida rose more than 38% this week, and its stock price hit a record high this week. In the first quarter of 2025, the company continued the trend of full production and sales in the fourth quarter of last year, compared with the same period last year, the drag impact of the loss of subsidiaries has been basically eliminated, and the overseas market has fully recovered, of which the growth rate of the European market exceeded 40%; The price of raw materials fluctuated little, the overall price of the sales side was stable, the sales structure was further optimized, and the comprehensive gross profit margin continued to increase.

Deyuan Pharmaceutical rose more than 28% this week, and its stock price also hit a record high: the company will achieve operating income of 868 million yuan in 2024, a year-on-year increase of 22.46%; the net profit was 177 million yuan, a year-on-year increase of 28.26%; realized a net profit of 170 million yuan, a year-on-year increase of 35.23%; In 2024, the net operating cash flow will be 116 million yuan, a year-on-year increase of 23.40%.